
Tapestry Pharmaceuticals Inc (AKA: NaPro BioTherapeutics Inc) Profile last edited on: 5/13/2019
CAGE:
UEI:
Business Identifier: Therapeutics from natural products Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
4840 Pearl East Circle Suite 300w
Boulder, CO 80301
Boulder, CO 80301
(303) 516-8500 |
info@tapestrypharma.com |
www.tapestrypharma.com |
Location: Multiple
Congr. District: 02
County: Boulder
Congr. District: 02
County: Boulder
Public Profile
Previously dba NaPro BioTherapeutics, Inc.Tapestry Pharmaceuticals, Inc. had been organized primarily around three elements: production and sale of Paclitaxel, an approved cancer drug; the development of targeted oncology products, and the development of novel genomic technologies, primarily in the area of gene editing for applications in human therapeutics, diagnostics, agribiotechnology and pharmacogenomics. Developing proprietary therapies for the treatment of cancer, the firm also was structured to evaluate new therapeutic agents and related technologies that involve the examination of individual molecules, classes of compounds, and platform technologies. The Company's commercialized product had been Paclitaxel, a naturally occurring chemotherapeutic anti-cancer agent found in certain species of yew, or Taxus, trees. The Company also worked on several types of compounds that have promising activity as anti-cancer agents. NaPro BioTherapeutics had been engaged in evaluating the in-licensing or purchase of potential new products and/or technologies, whether or not those products or technologies are derived from natural products. In December 2003, the Company sold its worldwide generic injectable Paclitaxel business to Mayne Pharma. Duirng the financial crises of 2008 the firm was delisted fromNASDAQ and filed for bankrupcy
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
25-49Revenue Range
2.5M-5MVC funded?
YesPublic/Private
Publicly TradedStock Info
NASDAQ : TPPHIP Holdings
50-74Awards Distribution by Agency
Most Recent SBIR Projects
Year | Phase | Agency | Total Amount | |
---|---|---|---|---|
2004 | 1 | NIH | $100,000 | |
Project Title: Selectable Editing of Gene Defects Affecting Solid Tissue |
Key People / Management
Leonard P Shaykin -- CEO
Leonard P Shaykin -- President
Martin Batt Sr -- VP, COO
David L David L -- VP Cancer Biology
Bruce W Fiedler -- VP, Corporate Controller
Lawrence Helson -- VP, Bio Research
Kai P Larson -- VP, General Counsel
Gordon Link Jr -- VP, CFO
James D McChesney -- CSO, Natural Products Chemistry
Patricia A Pilia -- Executive Vice President
Frank Tagliaferri
Leonard P Shaykin -- President
Martin Batt Sr -- VP, COO
David L David L -- VP Cancer Biology
Bruce W Fiedler -- VP, Corporate Controller
Lawrence Helson -- VP, Bio Research
Kai P Larson -- VP, General Counsel
Gordon Link Jr -- VP, CFO
James D McChesney -- CSO, Natural Products Chemistry
Patricia A Pilia -- Executive Vice President
Frank Tagliaferri